QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-94

HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price targ...

 generics-player-ani-pharmaceuticals-strengthens-rare-disease-segment-with-380m-alimera-sciences-deal

ANI Pharmaceuticals to acquire Alimera Sciences for $5.50 per share in cash, plus a contingent value right of up to $0.50 per s...

Core News & Articles

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("...

 ani-pharmaceuticals-has-launched-kionex-sodium-polystyrene-sulfonate-suspension-usp-for-oral-or-rectal-use

U.S. annual sales for Sodium Polystyrene Sulfonate Oral / Rectal Suspension total approximately $30.3 million, based on March 2...

 hc-wainwright--co-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-87

HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price targ...

 ani-pharmaceuticals-reiterates-fy24-outlook-of-520m-542m-vs-53511m-estimate-projects-fy24-adjusted-eps-of-426--467-vs-448-estimate

ANI continues to expect total company adjusted non-GAAP gross margin between 62% and 63% and the Company will continue to tax e...

 ani-pharmaceuticals-q1-adj-121-beats-100-estimate-sales-13743m-beat-126m-estimate

ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $...

 guggenheim-reiterates-buy-on-ani-pharmaceuticals-maintains-77-price-target

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $77 price target.

 ani-pharmaceuticals-announces-the-launch-of-baclofen-oral-suspension

U.S. annual sales for Baclofen Oral Suspension total approximately $39 million, according to IQVIA data.

 ani-pharmaceuticals-announces-the-launch-of-levofloxacin-oral-solution-usp

ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Levofloxacin Oral Solution, a generi...

 capital-one-initiates-coverage-on-ani-pharmaceuticals-with-overweight-rating

Capital One analyst Timothy Chiang initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Overweight rating.

 alphabet-dover-and-2-other-stocks-insiders-are-selling

The Nasdaq 100 closed lower by around 1.5% on Friday. Investors, meanwhile, focused on some notable insider trades.

 guggenheim-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-77

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $70 t...

 hc-wainwright--co-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-83

HC Wainwright & Co. analyst Oren Livnat maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price targ...

 truist-securities-maintains-buy-on-ani-pharmaceuticals-raises-price-target-to-80

Truist Securities analyst Gregory Fraser maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target ...